Abstract
It is recognized that radiation therapy can eradicate microscopic tumor disease, even in postoperative prostate cancer patients, when extracapsular extension, positive surgical margins or increased prostate-specific antigen is found in surgical specimens. This review of recent literature analyzes and discusses acquired certainties and still open questions regarding type, timing, doses, techniques, toxicities, and associated hormonal therapies of radiotherapy prescribed after radical prostatectomy.
MeSH terms
-
Biomarkers, Tumor / blood
-
Humans
-
Lymph Nodes / pathology
-
Lymph Nodes / radiation effects
-
Lymphatic Metastasis
-
Male
-
Neoplasm Staging
-
Patient Selection
-
Pelvis
-
Prostate-Specific Antigen / blood
-
Prostatectomy* / methods
-
Prostatic Neoplasms / immunology
-
Prostatic Neoplasms / pathology
-
Prostatic Neoplasms / radiotherapy*
-
Prostatic Neoplasms / surgery
-
Radiotherapy Dosage
-
Radiotherapy, Adjuvant / methods
-
Randomized Controlled Trials as Topic
-
Salvage Therapy
Substances
-
Biomarkers, Tumor
-
Prostate-Specific Antigen